A Safety Study of NNZ-2566 in Patients With Rett Syndrome
|ClinicalTrials.gov Identifier: NCT01703533|
Recruitment Status : Completed
First Posted : October 10, 2012
Last Update Posted : February 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Rett Syndrome||Drug: NNZ-2566 Drug: Placebo||Phase 2|
Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome.
This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||September 2014|
Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Placebo Comparator: Placebo (strawberry flavored solution)
Strawberry flavored solution and Water for Injection
Strawberry flavored solution and Water for Injection
Other Name: Strawberry flavored solution 0.5% v/v in Water for Injection
- Adverse events [ Time Frame: Through to Day 40 ]Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. SAEs will be examined from randomization through to Day 40. AEs will be examined from dosing through to Day 40.
- Change in EEG activity [ Time Frame: Baseline through to Day 40 ]
Absolute change in the number of spikes in the EEG per hour during the awake state will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
Absolute change in the power of frequency bands in the EEG over an hour in the awake state as determined by the Fast Fourier method will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
Changes in the frequency of the characteristic repetitive stereotypic hand movements during wakefulness will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
- Behavior [ Time Frame: Baseline through to Day 40 ]
The following measures will be assessed at baseline and Day 26 and the changes compared between active and placebo groups:
Symptom severity according to the Rett Syndrome Natural History Motor Behavior Assessment (MBA), Clinical Severity Scale (CSS), Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scale (VABS), and Clinical Global Impression of Severity (CGI-S).
The following assessments will be undertaken at the additional time points specified: CGI-S (screening, baseline, Days 5, 14, 26, and 40), CGI-I (Days 5, 14, 26, and 40), MBA (Baseline, Days 26 and 40), CSS (screening, baseline, Days 26, and 40).
- Physiological changes [ Time Frame: Baseline through to Day 40 ]Changes in autonomic function, i.e. respiratory rhythm, hyperventilation, apneas, oxygen desaturation, and heart rate variation will be calculated between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
- Global and Functional outcome Measures [ Time Frame: Baseline through to Day 40 ]
Global outcome as measured by the change in scores on the Rett Syndrome Clinical Severity Score (CSS), The Rett Syndrome Motor-Behavior Assessment Scale (MBA), and the Clinical Global Impression - Severity and Improvement scales (CGI-S and -I) from baseline, during treatment, and post treatment.
Changes in caregiver assessment of the top three causes for concern as assessed via a Visual Analogue Scale (VAS) will be evaluated for each subject between baseline (pre-treatment), during treatment (Day 26) and after treatment (Day 40).
Changes in the Aberrant Behavior Checklist (ABC) and Vineland Adaptive Behavior Scales (VABS) will be calculated for each subject between baseline (pre-treatment), and during treatment (Day 26).
- Pharmacokinetics [ Time Frame: Baseline through to Day 40 ]The following pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood: Tmax, Cmax (peak), Cmin (trough), CAV at steady state, T1/2 and AUC.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01703533
|United States, Alabama|
|University of Alabama|
|Birmingham, Alabama, United States, 35294-0113|
|United States, Minnesota|
|Gillette Children's Specialty Healthcare|
|Saint Paul, Minnesota, United States, 55101|
|United States, Texas|
|Baylor School of Medicine|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Daniel G Glaze, M.D.||Baylor College of Medicine|
|Principal Investigator:||Jeffrey L Neul, M.D., Ph.D.||Baylor College of Medicine|
|Principal Investigator:||Alan Percy, MD||University of Alabama at Birmingham|
|Principal Investigator:||Timothy Feyma, MD||Gillette Children's Specialty Healthcare|
|Principal Investigator:||Arthur Beisang, MD||Gillette Children's Specialty Healthcare|